Modeling the Potential Role of Inactivated Poliovirus Vaccine to Manage the Risks of Oral Poliovirus Vaccine Cessation
Open accessThe DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Abstract
Background The Global Polio Eradication Initiative plans to stop all oral poliovirus vaccine (OPV) after wild poliovirus eradication, starting with serotype 2. Stakeholders continue to discuss the role of using inactivated poliovirus vaccine (IPV) to manage the risks of circulating vaccine-derived polioviruses (cVDPVs) during the end game. Methods We use a poliovirus transmission and OPV evolution model to explore the impact of various routine immunization policies involving IPV on population immunity dynamics and the probability and magnitude of cVDPV emergences following OPV cessation. Results Adding a single IPV dose to an OPV-only routine immunization schedule at or just before OPV cessation produces very limited impact on the probability of cVDPV emergences and the number of expected polio cases in settings in which we expect cVDPVs in the absence of IPV use. The highest-cost option of switching to a 3-dose IPV schedule only marginally decreases cVDPV risks. Discontinuing supplemental immunization activities while introducing IPV prior to OPV cessation leads to an increase in cVDPV risks. Conclusions Introducing a dose of IPV in countries currently using OPV only for routine immunization offers protection from paralysis to successfully vaccinated recipients, but it does little to protect high-risk populations from cVDPV risks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diekmann, O., Heesterbeek, J. A. P., & Metz, J. A. J. (1990) · Journal of Mathematical Biology · doi:10.1007/bf00178324 · Cited by 5,091
VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION
Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R., & Pallansch, M. A. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.58.030603.123625 · Cited by 703
Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review.
Patriarca, P. A., Wright, P. F., & John, T. J. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.5.926 · Cited by 453
Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines
Onorato, I. M., Modlin, J. F., McBean, A. M., Thoms, M. L., Losonsky, G. A., & Bernier, R. H. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.1.1 · Cited by 246
Hird, T. R., & Grassly, N. C. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002599 · Cited by 221
Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93
Oostvogel, P. M., van der Avoort, H. G. A. M., Mulders, M. N., van Loon, A. M., Conyn-van Spaendonck, M. A. E., Rümke, H. C., van Steenis, G., & van Wijngaarden, J. K. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92091-5 · Cited by 220
Vaccine Policy Changes and Epidemiology of Poliomyelitis in the United States
Alexander, L. N. (2004) · JAMA · doi:10.1001/jama.292.14.1696 · Cited by 203
Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication
Tebbens, R. J. D., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Jafari, H., Cochi, S. L., Sutter, R. W., Aylward, R. B., & Thompson, K. M. (2006) · Risk Analysis · doi:10.1111/j.1539-6924.2006.00827.x · Cited by 174
Self-citationInsidious reintroduction of wild poliovirus into Israel, 2013
Anis, E., Kopel, E., Singer, S. R., Kaliner, E., Moerman, L., Moran-Gilad, J., Sofer, D., Manor, Y., Shulman, L. M., Mendelson, E., et al. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.38.20586 · Cited by 162
Priming after a Fractional Dose of Inactivated Poliovirus Vaccine
Resik, S., Tejeda, A., Sutter, R. W., Diaz, M., Sarmiento, L., Alemañi, N., Garcia, G., Fonseca, M., Hung, L. H., Kahn, A.-L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1202541 · Cited by 139
Expert Review on Poliovirus Immunity and Transmission
Duintjer Tebbens, R. J., Pallansch, M. A., Chumakov, K. M., Halsey, N. A., Hovi, T., Minor, P. D., Modlin, J. F., Patriarca, P. A., Sutter, R. W., Wright, P. F., et al. (2013) · Risk Analysis · doi:10.1111/j.1539-6924.2012.01864.x · Cited by 109
Self-citationA Dynamic Model of Poliomyelitis Outbreaks: Learning from the Past to Help Inform the Future
Tebbens, R. J. D., Pallansch, M. A., Kew, O. M., Cáceres, V. M., Sutter, R. W., & Thompson, K. M. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi206 · Cited by 106
Self-citationTebbens, R. J. D., Pallansch, M. A., Kim, J., Burns, C. C., Kew, O. M., Oberste, M. S., Diop, O. M., Wassilak, S. G. F., Cochi, S. L., & Thompson, K. M. (2013) · Risk Analysis · doi:10.1111/risa.12022 · Cited by 105
Self-citationTebbens, R. J. D., Pallansch, M. A., Kalkowska, D. A., Wassilak, S. G. F., Cochi, S. L., & Thompson, K. M. (2013) · Risk Analysis · doi:10.1111/risa.12044 · Cited by 95
Self-citationBENYESH-MELNICK, M., MELNICK, J. L., RAWLS, W. E., WIMBERLY, I., ORO, J. B., BEN-PORATH, E., & RENNICK, V. (1967) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120717 · Cited by 93
Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa054960 · Cited by 90
Kohler, K. A., Banerjee, K., Hlady, W. G., Andrus, J. K., & Sutter, R. W. (2002) · Europe PMC (PubMed Central) · Cited by 88
Modeling the Dynamics of Oral Poliovirus Vaccine Cessation
Thompson, K. M., & Tebbens, R. J. D. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit845 · Cited by 84
Self-citationThe Risks, Costs, and Benefits of Possible Future Global Policies for Managing Polioviruses
Thompson, K. M., Tebbens, R. J. D., Pallansch, M. A., Kew, O. M., Sutter, R. W., Aylward, R. B., Watkins, M., Gary, H. E., Alexander, J. P., Jafari, H. S., et al. (2008) · American Journal of Public Health · doi:10.2105/ajph.2007.122192 · Cited by 81
Self-citationOutbreaks of Paralytic Poliomyelitis, 1976-1995
Patriarca, P. A., Sutter, R. W., & Oostvogel, P. M. (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s165 · Cited by 77
Tebbens, R. J. D., Pallansch, M. A., Chumakov, K. M., Halsey, N. A., Hovi, T., Minor, P. D., Modlin, J. F., PATRIARCA, P. A., Sutter, R. W., Wright, P. F., et al. (2013) · Risk Analysis · doi:10.1111/risa.12031 · Cited by 75
Self-citationLIMITATION OF FECAL AND PHAEYNGEAL POLIOVIEUSEXCRETION IN SALK-VACCINATED CHILDREN
MARINE, W. M., CHIN, T. D. Y., & GRAVELLE, C. R. (1962) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120272 · Cited by 75
Interrupting the transmission of wild polioviruses with vaccines: immunological considerations.
(1994) · Europe PMC (PubMed Central) · Cited by 70
Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses
Thompson, K. M., Pallansch, M. A., Tebbens, R. J. D., Wassilak, S. G. F., & Cochi, S. L. (2012) · Risk Analysis · doi:10.1111/j.1539-6924.2012.01891.x · Cited by 70
Self-citationPoliovirus vaccination options for achieving eradication and securing the endgame
Estívariz, C. F., Pallansch, M. A., Anand, A., Wassilak, S. G., Sutter, R. W., Wenger, J. D., & Orenstein, W. A. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.05.007 · Cited by 66
Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control
Thompson, K. M., Pallansch, M. A., Tebbens, R. J. D., Wassilak, S. G. F., Kim, J., & Cochi, S. L. (2013) · Risk Analysis · doi:10.1111/risa.12019 · Cited by 59
Self-citationLago, P. M., Bravo, J. R., Andrus, J. K., Comellas, M. M., Galindo-Izquierdo, M., de Quadrós, C. A., & Bell, E. (1994) · Europe PMC (PubMed Central) · Cited by 58
Elimination of Poliomyelitis in Finland
Lapinleimu, K. (1984) · Clinical Infectious Diseases · doi:10.1093/clinids/6.supplement_2.s457 · Cited by 57
The potential impact of expanding target age groups for polio immunization campaigns
Tebbens, R. J. D., Kalkowska, D. A., Wassilak, S. G. F., Pallansch, M. A., Cochi, S. L., & Thompson, K. M. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-45 · Cited by 53
Self-citationKalkowska, D. A., Tebbens, R. J. D., & Thompson, K. M. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit844 · Cited by 47
Self-citationKalkowska, D. A., Tebbens, R. J. D., & Thompson, K. M. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit834 · Cited by 44
Self-citationThompson, K. M., & Tebbens, R. J. D. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2014.864563 · Cited by 43
Self-citationTransmission of wild poliovirus type 2--apparent global interruption.
(2001) · PubMed · Cited by 40
Chin, T. D. Y., Marine, W. M., Hall, E. C., Gravelle, C. R., & Speers, J. F. (1961) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120202 · Cited by 31
Chin, T. D. Y., Marine, W. M., Hall, E. C., Gravelle, C. R., & Speers, J. F. (1962) · Nursing Research · doi:10.1097/00006199-196201120-00033 · Cited by 13
Research works printed but not linked: 1
- World Health Organization, 2005, Cessation of Routine Oral Polio Vaccine (OPV) use after Global Polio Eradication: framework for national policy makers in OPV-using countries
Cited by
Modeling the Dynamics of Oral Poliovirus Vaccine Cessation
Thompson, K. M., & Tebbens, R. J. D. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit845 · Cited by 84
“Given the plans for OPV2 cessation, we use model inputs for type 2 [14, 17], although the concepts of this analysis extend to the other 2 serotypes.”
BackgroundMethodInfluentialSelf-citationPolio endgame: the global switch from tOPV to bOPV
Garon, J. R., Seib, K. G., Orenstein, W. A., Gonzalez, A. R., Blanc, D. C., Zaffran, M., & Patel, M. M. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1140041 · Cited by 85
Polio endgame: the global introduction of inactivated polio vaccine
Patel, M. M., Zipursky, S., Orenstein, W., Garon, J. R., & Zaffran, M. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1001750 · Cited by 77
“However, if IPV protects against paralytic disease but has little impact against fecal-oral transmission, modeling suggests that IPV would not contribute toward interruption of transmission in the context of an outbreak in settings of high force of infection [43].”
BackgroundAn economic analysis of poliovirus risk management policy options for 2013–2052
Tebbens, R. J. D., Pallansch, M. A., Cochi, S. L., Wassilak, S. G. F., & Thompson, K. M. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1112-8 · Cited by 73
“We assume tOPV intensification leading up to OPV2 cessation maximizes population immunity at OPV2 cessation and avoids cVDPV2 emergences after OPV2 cessation [24, 52] and sufficient bOPV use before OPV13 cessation to avoid subsequent cVDPVs.”
BackgroundMethodInfluentialSelf-citationModeling Options to Manage Type 1 Wild Poliovirus Imported Into Israel in 2013
Kalkowska, D. A., Tebbens, R. J. D., Grotto, I., Shulman, L. M., Anis, E., Wassilak, S. G. F., Pallansch, M. A., & Thompson, K. M. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu674 · Cited by 65
“Further studies should continue to explore the dynamics of population immunity and OPV cessation [22, 23, 29, 30].”
Self-citation
Metadata
- Authors
- Duintjer Tebbens, R. J., & Thompson, K. M.
- Affiliations
- University of Central Florida (US)
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-11
- Volume
- 210
- Issue
- suppl_1
- Pages
- S485-S497
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2054025229
- Cited by
- 48
- References
- 39
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 6 · 2016: 9 · 2015: 10 · 2014: 3
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Journal of International Crisis and Risk Communication Research (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Applied Mathematics › Mathematical and Theoretical Epidemiology and Ecology Models
- Keywords
- inactivated poliovirus vaccine, circulating vaccine-derived poliovirus, supplementary immunization activities, polio eradication
- MeSH terms
- Computer Simulation, Humans, Poliomyelitis, Poliovirus Vaccine, Inactivated, Poliovirus Vaccine, Oral, Vaccination, Disease Eradication
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.